Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

102 results

Filters applied: . Clear all
Page 1
An update on inclisiran for the treatment of elevated LDL cholesterol.
Barkas F, Ray K. Barkas F, et al. Among authors: ray k. Expert Opin Pharmacother. 2024 Apr 8:1-10. doi: 10.1080/14656566.2024.2337253. Online ahead of print. Expert Opin Pharmacother. 2024. PMID: 38549399 Review.
To optimize inclisiran's utilization and comprehend its long-term effects, future directions include pediatric studies, cardiovascular outcome trials, and extended-duration investigations. ...
To optimize inclisiran's utilization and comprehend its long-term effects, future directions include pediatric studies, cardiovascula …
Safety and Tolerability of Inclisiran for Treatment of Hypercholesterolemia in 7 Clinical Trials.
Wright RS, Koenig W, Landmesser U, Leiter LA, Raal FJ, Schwartz GG, Lesogor A, Maheux P, Stratz C, Zang X, Ray KK. Wright RS, et al. Among authors: ray kk. J Am Coll Cardiol. 2023 Dec 12;82(24):2251-2261. doi: 10.1016/j.jacc.2023.10.007. J Am Coll Cardiol. 2023. PMID: 38057066 Free article.
OBJECTIVES: The purpose of this study was to provide reliable evidence to date on the long-term safety profile of inclisiran. METHODS: This post hoc analysis comprised patients treated with 300 mg inclisiran sodium or placebo in the completed (ORION-1, -3, -5, -9, -10, and …
OBJECTIVES: The purpose of this study was to provide reliable evidence to date on the long-term safety profile of inclisiran. METHODS …
Non-HDL-cholesterol in dyslipidemia: Review of the state-of-the-art literature and outlook.
Raja V, Aguiar C, Alsayed N, Chibber YS, ElBadawi H, Ezhov M, Hermans MP, Pandey RC, Ray KK, Tokgözoglu L, Zambon A, Berrou JP, Farnier M. Raja V, et al. Among authors: ray kk. Atherosclerosis. 2023 Oct;383:117312. doi: 10.1016/j.atherosclerosis.2023.117312. Epub 2023 Sep 30. Atherosclerosis. 2023. PMID: 37826864 Free article. Review.
In addition, large follow-up studies have reported that individuals with higher baseline non-HDL-C at a younger age (<45 years) were more prone to adverse CVD events at an older age, suggesting a predictive ability of non-HDL-C over the long term. Consequently, non-HDL- …
In addition, large follow-up studies have reported that individuals with higher baseline non-HDL-C at a younger age (<45 years) were more …
Triheptanoin for the treatment of long-chain fatty acid oxidation disorders: Final results of an open-label, long-term extension study.
Vockley J, Burton BK, Berry G, Longo N, Phillips J, Sanchez-Valle A, Chapman KA, Tanpaiboon P, Grunewald S, Murphy E, Lu X, Rahman S, Ray K, Reineking B, Pisani L, Ramirez AN. Vockley J, et al. Among authors: ray k. J Inherit Metab Dis. 2023 Sep;46(5):943-955. doi: 10.1002/jimd.12640. Epub 2023 Jun 19. J Inherit Metab Dis. 2023. PMID: 37276053 Clinical Trial.
Study CL202 (NCT02214160), an open-label extension study of study CL201 (NCT01886378), evaluated the long-term safety/efficacy of triheptanoin in patients with LC-FAODs (N = 94), including cohorts who were triheptanoin naive (n = 33) or had received triheptanoin in study C …
Study CL202 (NCT02214160), an open-label extension study of study CL201 (NCT01886378), evaluated the long-term safety/efficacy of tri …
Long-term treatment persistence and maintained reduction of LDL-cholesterol levels with evolocumab over 30 months: Results from the Spanish cohort of the European prospective HEYMANS study.
Blanco Echevarría A, García Díaz JD, Caixas A, Plana Gil N, Rico Corral MÁ, Bridges I, Dhalwani N, Gatell Menchen S, Ray KK. Blanco Echevarría A, et al. Among authors: ray kk. Clin Investig Arterioscler. 2023 Nov-Dec;35(6):263-271. doi: 10.1016/j.arteri.2023.04.004. Epub 2023 May 24. Clin Investig Arterioscler. 2023. PMID: 37236829 Free article. English, Spanish.
AIMS: Limited data exist on low-density lipoprotein-cholesterol (LDL-C) level variability or long-term persistence with the monoclonal antibody evolocumab in routine clinical practice. ...
AIMS: Limited data exist on low-density lipoprotein-cholesterol (LDL-C) level variability or long-term persistence with the monoclona …
Metabolic syndrome is associated with similar long-term prognosis in those living with and without obesity: an analysis of 45 615 patients from the nationwide LIPIDOGRAM 2004-2015 studies.
Osadnik K, Osadnik T, Gierlotka M, Windak A, Tomasik T, Mastej M, Kuras A, Jóźwiak K, Penson PE, Lip GYH, Mikhailidis DP, Toth PP, Catapano AL, Ray KK, Howard G, Tomaszewski M, Charchar FJ, Sattar N, Williams B, MacDonald TM, Banach M, Jóźwiak J. Osadnik K, et al. Among authors: ray kk. Eur J Prev Cardiol. 2023 Sep 6;30(12):1195-1204. doi: 10.1093/eurjpc/zwad101. Eur J Prev Cardiol. 2023. PMID: 37039119
AIMS: We aimed to evaluate the association between metabolic syndrome (MetS) and long-term all-cause mortality. METHODS AND RESULTS: The LIPIDOGRAM studies were carried out in the primary care in Poland in 2004, 2006, and 2015. ...An additional finding, which is important …
AIMS: We aimed to evaluate the association between metabolic syndrome (MetS) and long-term all-cause mortality. METHODS AND RESULTS: …
Healthcare Utilization Among Children Receiving Permanent Supportive Housing.
Bohnhoff JC, Xue L, Hollander MAG, Burgette JM, Cole ES, Ray KN, Donohue J, Roberts ET. Bohnhoff JC, et al. Among authors: ray kn. Pediatrics. 2023 Apr 1;151(4):e2022059833. doi: 10.1542/peds.2022-059833. Pediatrics. 2023. PMID: 36974602 Free PMC article.
BACKGROUND AND OBJECTIVES: Permanent supportive housing (PSH) integrates long-term housing and supports for families and individuals experiencing homelessness. ...
BACKGROUND AND OBJECTIVES: Permanent supportive housing (PSH) integrates long-term housing and supports for families and individuals …
Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial.
Schwartz GG, Szarek M, Bhatt DL, Bittner VA, Bujas-Bobanovic M, Diaz R, Fazio S, Fras Z, Goodman SG, Harrington RA, Jukema JW, Manvelian G, Pordy R, Ray KK, Scemama M, White HD, Steg PG; ODYSSEY OUTCOMES Investigators. Schwartz GG, et al. Among authors: ray kk. Eur Heart J. 2023 Mar 5;44(16):1408-17. doi: 10.1093/eurheartj/ehad144. Online ahead of print. Eur Heart J. 2023. PMID: 36879424 Free PMC article.
AIMS: Long-term, placebo-controlled cholesterol-lowering trials have demonstrated legacy effects (clinical benefits that persist or emerge after trial end). ...
AIMS: Long-term, placebo-controlled cholesterol-lowering trials have demonstrated legacy effects (clinical benefits that persist or e …
Long-term persistence with evolocumab treatment and sustained reductions in LDL-cholesterol levels over 30 months: Final results from the European observational HEYMANS study.
Ray KK, Bruckert E, Peronne-Filardi P, Ebenbichler C, Vogt A, Bridges I, Sibartie M, Dhalwani N. Ray KK, et al. Atherosclerosis. 2023 Feb;366:14-21. doi: 10.1016/j.atherosclerosis.2023.01.002. Epub 2023 Jan 13. Atherosclerosis. 2023. PMID: 36696747 Free article.
BACKGROUND AND AIMS: Variability in low-density lipoprotein-cholesterol (LDL-C) level control at a population level is associated with poor cardiovascular outcomes. Limited data exist on LDL-C level variability or long-term persistence with the monoclonal antibody evolocum …
BACKGROUND AND AIMS: Variability in low-density lipoprotein-cholesterol (LDL-C) level control at a population level is associated with poor …
102 results